Summary of Key Points
New Novo (now renamed “Shiye Innovation”) was once the world's largest caffeine producer, generating substantial profits by supplying Coca-Cola and Red Bull. However, after 2022, both the volume and price of its caffeine business declined, weakening its risk resilience due to its reliance on a single product. To transform into an innovative pharmaceutical company, the firm acquired Jushi Biology (specializing in ADCs, monoclonal antibodies, and other innovative drugs) under the Shiye Group and changed its name to “Shiye Innovation” in 2026. During this transition, rapid increases in research and development (R&D) expenses led to a loss for the first time in 2025. Nevertheless, in the first half of 2026, the company turned a profit by receiving an upfront payment of $420 million from AstraZeneca. Despite ongoing challenges such as declining caffeine sales and difficulties in growing innovative drug sales, the success of this transformation remains to be proven over the long term.
Detailed Analysis
1. The Name Change Represents a Complete Shift in Focus
New Novo was once the “King of Caffeine,” with nearly 50% global market share and generating profits like a “money-making machine” by supplying the three major beverage giants. However, after 2022, caffeine prices dropped (returning to levels seen from 2017-2020), and sales volumes also decreased (a 6.77% year-on-year decline in the first ten months of 2023). Additionally, the plummeting prices of raw materials for health food products exposed the vulnerability of this single business model.
To break this pattern, the company acquired 80% of Jushi Biology’s shares over 2023-2025 (Jushi Biology is Shiye Group’s platform for innovative drugs, focusing on ADCs and mRNA vaccines), expanding its business from caffeine sales to biopharmaceutical innovation. The name change to “Shiye Innovation” signals to the market that it has evolved from a raw material supplier to an innovator in the pharmaceutical industry—a transformation akin to moving from a traditional factory to a technology company.
2. The Once-Profitable Caffeine Business Is Losing Its Edge
The caffeine business was once a major source of revenue, but its profitability is declining:
- Revenue from functional ingredients (mainly caffeine) and health food products grew by only 0.93% in 2025, with gross margins falling by 4.85 percentage points, starting to drag down overall profits.
- Although this business still accounts for 88.4% of total revenue (in the first seven months of 2025) and provides necessary cash flow for the transformation, its contribution is weakening as its own profits shrink.
The critical question is whether the caffeine business will continue to support the company until its innovative drugs start generating significant profits. If caffeine sales continue to decline, the resources needed for innovation may become insufficient.
3. The Innovative Drug Business Is Still Emerging
Jushi Biology’s innovative drug division showed impressive growth (192.65% year-on-year in 2025), but its scale is still small, with annual revenue of only 257 million yuan, accounting for 11.9% of total sales. This is far from enough to offset the decline in traditional business revenues and cover R&D expenses.
The challenge of selling innovative drugs is even greater: The revenue from core innovative drugs in 2025 was insufficient to cover the company’s marketing costs (281 million yuan). For example, the PD-1 monoclonal antibody market is highly competitive, and domestic competitors have already entered the space. Innovative drugs require not only approval but also distribution through hospitals and physician prescriptions to recoup costs—a process that takes longer than expected.
4. R&D Expenses Led to a Loss in 2025, but AstraZeneca Provided Relief
In 2025, the company incurred a loss of 241 million yuan, mainly due to high R&D expenses (1.036 billion yuan, or 48% of revenue), plus Jushi Biology’s losses (904 million yuan, which affected the parent company by about 270 million yuan). A turning point came in January 2026 when Jushi Biology signed a cooperation agreement with AstraZeneca, securing an upfront payment of $420 million (about 3 billion yuan), which helped the company turn a profit in the second quarter. This funding not only resolved short-term financial issues but also boosted its reputation as an innovative company, as AstraZeneca is a global pharmaceutical leader investing in Shiye Innovation’s pipeline. Subsequent agreements further strengthened this recognition.
5. The Transformation Is Just Beginning
Although Shiye Innovation has turned a profit and gained recognition from industry giants, the challenges remain:
- The caffeine business continues to shrink, reducing cash flow for transformation.
- R&D efforts will continue as new products are developed, and sales of innovative drugs need time to grow.
- The future success depends on the progress of these products—Ustnu monoclonal antibody has already been launched, Patuzumab is in the approval process, and several ADCs are in Phase III clinical trials. Whether these products will be successful is key to the company’s long-term growth.
In summary, this transformation represents a shift from low-value raw material sales to high-value innovative drugs in China’s pharmaceutical industry. While cooperation with giants has helped the company avoid losses, true success requires balancing support from traditional businesses with sustained growth from innovative initiatives. Transformation is never immediate; it requires time, investment, and patience.